Evaluation_NN of_IN Antibiotic_JJ Susceptibilities_NNS of_IN Three_NP Rickettsial_NP Species_NP Including_NP Rickettsia_NP felis_NP by_IN a_DT Quantitative_NP PCR_NP DNA_NP Assay_NP Rickettsiae_NP grow_VBP only_RB intracellularly_RB ,_, and_CC the_DT antibiotic_JJ susceptibilities_NNS of_IN these_DT bacteria_NNS have_VBP been_VBN assessed_VBN by_IN either_DT plaque_NN ,_, dye_NN uptake_NN ,_, or_CC immunofluorescence_NN assays_NNS ,_, which_WDT are_VBP time-consuming_JJ ._SENT We_PP used_VBD a_DT quantitative_JJ PCR_NP (_( with_IN the_DT LightCycler_NP instrument_NN )_) to_TO assess_VB the_DT levels_NNS of_IN inhibition_NN of_IN Rickettisa_NP felis_NP ,_, R._NP conorii_NP ,_, and_CC R._NP typhi_NP DNA_NP synthesis_NN in_IN the_DT presence_NN of_IN various_JJ antibiotics_NNS ._SENT We_PP established_VBD the_DT kinetics_NN of_IN rickettsial_JJ DNA_NN during_IN growth_NN and_CC showed_VBD that_IN R._NP conorii_NP grows_VBZ more_RBR quickly_RB than_IN R._NP typhi_NNS in_IN cell_NN culture_NN ,_, with_IN maximum_JJ replication_NN occurring_VBG after_IN 5_CD and_CC 7_CD days_NNS ,_, respectively_RB ._SENT The_DT MICs_NP of_IN the_DT antibiotics_NNS tested_VBN for_IN R._NP conorii_NP and_CC R._NP typhi_NNS by_IN the_DT quantitative_JJ PCR_NP assay_NN were_VBD similar_JJ to_TO those_DT previously_RB obtained_VBN by_IN plaque_NN and_CC dye_NN uptake_NN assays_NNS ._SENT We_PP found_VBD that_IN R._NP felis_NP is_VBZ susceptible_JJ to_TO doxycycline_NN ,_, rifampin_NN ,_, thiamphenicol_NN ,_, and_CC fluoroquinolones_NNS but_CC not_RB to_TO gentamicin_NN ,_, erythromycin_NN ,_, amoxicillin_NN ,_, or_CC trimethoprim-sulfamethoxazole_NN ._SENT The_DT resistance_NN of_IN this_DT new_JJ species_NN to_TO erythromycin_NN is_VBZ consistent_JJ with_IN its_PP$ current_JJ taxonomic_JJ position_NN within_IN the_DT spotted_JJ fever_NN group_NN ._SENT We_PP believe_VBP that_IN quantitative_JJ PCR_NP could_MD be_VB used_VBN in_IN the_DT future_NN to_TO simplify_VB and_CC shorten_VB antibiotic_JJ susceptibility_NN assays_NNS of_IN other_JJ rickettsiae_NNS and_CC other_JJ strict_JJ intracellular_JJ pathogens_NNS ._SENT Rickettsiae_NNS are_VBP strict_JJ intracellular_JJ bacteria_NNS belonging_VBG to_TO the_DT alpha_NN group_NN of_IN the_DT class_NN Proteobacteria_NN ._SENT Rickettsioses_NNS are_VBP zoonoses_NNS that_WDT have_VBP geographical_JJ distributions_NNS similar_JJ to_TO those_DT of_IN their_PP$ vectors_NNS ._SENT The_DT genus_NN comprises_VBZ the_DT spotted_JJ fever_NN group_NN rickettsiae_NNS and_CC the_DT typhus_NN group_NN rickettsiae_NNS ,_, which_WDT includes_VBZ Rickettsia_NP prowazekii_NP ,_, the_DT agent_NN of_IN epidemic_JJ typhus_NN ,_, and_CC R._NP typhi_NP ,_, the_DT agent_NN of_IN murine_JJ typhus_NN ._SENT Since_IN they_PP are_VBP obligate_JJ intracellular_JJ bacteria_NNS ,_, in_IN vitro_NN studies_NNS of_IN their_PP$ susceptibilities_NNS to_TO antibiotics_NNS necessitate_VBP the_DT use_NN of_IN cell_NN culture_NN systems_NNS ._SENT Using_VBG the_DT plaque_NN assay_NN and_CC the_DT dye_NN uptake_NN assay_NN ,_, we_PP have_VBP now_RB described_VBN the_DT antibiotic_JJ susceptibilities_NNS of_IN most_JJS of_IN the_DT rickettsiae_NNS with_IN the_DT exception_NN of_IN R._NP felis_NP ,_, which_WDT ,_, until_IN recently_RB ,_, was_VBD not_RB available_JJ to_TO us_PP ._SENT The_DT two_CD assays_NNS depend_VBP on_IN the_DT induction_NN of_IN cytopathic_JJ effects_NNS and_CC plaque_NN formation_NN in_IN cell_NN cultures_NNS by_IN the_DT rickettsiae_NNS ,_, but_CC some_DT rickettsiae_NNS do_VBP not_RB normally_RB cause_VB cytopathic_JJ effects_NNS in_IN primary_JJ cultures_NNS ._SENT Recently_RB ,_, Ives_NP et_FW al._FW (_( -_: )_) described_VBD a_DT new_JJ assay_NN that_WDT uses_VBZ immunofluorescence_NN staining_VBG ,_, which_WDT avoids_VBZ the_DT problem_NN of_IN a_DT lack_NN of_IN cytopathic_JJ effects_NNS ._SENT A_DT lack_NN of_IN cytopathic_JJ effects_NNS occurs_VBZ with_IN R._NP felis_NP ,_, the_DT agent_NN of_IN flea-borne_JJ spotted_JJ fever_NN ,_, which_WDT we_PP have_VBP now_RB isolated_VBN and_CC cultured_VBN in_IN a_DT Xenopus_NP laevis_NN cell_NN line_NN (_( XTC-2_JJ cells_NNS )_) and_CC in_IN Vero_NP cells_NNS ._SENT To_TO determine_VB the_DT antibiotic_JJ susceptibility_NN of_IN this_DT species_NNS we_PP developed_VBD an_DT original_JJ antibiotic_JJ assay_NN using_VBG PCR_NP with_IN the_DT LightCycler_NP instrument_NN ._SENT It_PP is_VBZ a_DT new_JJ ,_, real-time_JJ PCR_NP technique_NN which_WDT has_VBZ been_VBN used_VBN to_TO diagnose_VB several_JJ bacterial_JJ infections_NNS but_CC which_WDT has_VBZ not_RB been_VBN used_VBN to_TO determine_VB antibiotic_JJ susceptibilities_NNS ._SENT The_DT technique_NN combines_VBZ PCR_NP amplification_NN and_CC detection_NN of_IN products_NNS in_IN a_DT single_JJ optically_RB clear_JJ glass_NN capillary_NN tube_NN ,_, which_WDT enables_VBZ rapid_JJ temperature_NN transitions_NNS with_IN hot_JJ air_NN and_CC which_WDT reduces_VBZ the_DT PCR_NP time_NN to_TO 45_CD min_NN ._SENT In_IN this_DT report_NN we_PP describe_VBP the_DT PCR_NP method_NN with_IN the_DT LightCycler_NP instrument_NN that_IN we_PP developed_VBD for_IN antibiotic_JJ susceptibility_NN testing_NN of_IN Rickettsia_NP isolates_VBZ ._SENT Furthermore_RB ,_, we_PP report_VBP on_IN the_DT antibiotic_JJ susceptibilities_NNS that_IN we_PP obtained_VBD for_IN R._NP felis_NP ,_, R._NP conorii_NP ,_, and_CC R._NP typhi_NNS and_CC compare_VB these_DT susceptibilities_NNS with_IN those_DT obtained_VBN by_IN the_DT plaque_NN assay_NN ,_, the_DT reference_NN method_NN ._SENT Rickettsial_JJ isolates_NNS ._SENT |_SYM Four_CD isolates_NNS of_IN R._NP felis_NP from_IN fleas_NNS were_VBD used_VBN in_IN the_DT study_NN :_: Marseille-URRWFXCal2_NP I-2363_NP (_( Cal2_NP )_) ,_, Pete2_NP ,_, Marseille_NP ,_, and_CC Baton_NP Rouge_NP ._SENT They_PP were_VBD cultured_VBN in_IN XTC-2_JJ cells_NNS with_IN Leibowitz-15_NP medium_NN (_( 2_CD mM_NP l-glutamine_NN and_CC amino_NN acids_NNS in_IN the_DT l_NN configuration_NN ;_: Gibco_NP )_) containing_VBG 5_CD %_NN fetal_JJ calf_NN serum_NN and_CC 2_CD %_NN tryptose_NN phosphate_NN (_( Gibco_NP )_) ,_, as_RB described_VBN previously_RB ._SENT Also_RB used_VBN were_VBD R._NP conorii_NP (_( ATCC_NP VR-141_NP )_) ,_, the_DT agent_NN of_IN Mediterranean_JJ spotted_JJ fever_NN ,_, and_CC the_DT R._NP typhi_NP Wilmington_NP strain_NN (_( ATCC_NP VR-144_NP )_) ,_, the_DT agent_NN of_IN murine_JJ typhus_NN ,_, which_WDT were_VBD grown_VBN in_IN Vero_NP cells_NNS in_IN minimum_JJ essential_JJ medium_NN at_IN 32C_JJ with_IN 2_CD mM_NP l-glutamine_NP (_( Gibco_NP )_) containing_VBG 4_CD %_NN fetal_JJ calf_NN serum_NN ._SENT Antibiotics_NNS ._SENT |_SYM The_DT antibiotics_NNS tested_VBN were_VBD amoxicillin_NP (_( Beecham-Sevigne_NP ,_, Paris_NP ,_, France_NP )_) ,_, gentamicin_NN (_( Dakota_NP Pharm_NP ,_, Creteil_NP ,_, France_NP )_) ,_, ciprofloxacin_NP (_( Bayer_NP Pharma_NP ,_, Sebs_NP ,_, France_NP )_) ,_, erythromycin_NN (_( Abbott_NP ,_, Rungis_NP ,_, France_NP )_) ,_, rifampin_NP (_( Cassenne_NP ,_, Puteaux_NP ,_, France_NP )_) ,_, doxycycline_NP (_( Pfizer_NP ,_, Neuilly_NP ,_, France_NP )_) ,_, telithromycin_NP (_( Hoescht_NP Marion_NP Roussel_NP ,_, Romainville_NP ,_, France_NP )_) ,_, levofloxacin_NP (_( Hoescht_NP Marion_NP Roussel_NP )_) ,_, ofloxacin_NP (_( Diamant_NP ,_, Puteaux_NP ,_, France_NP )_) ,_, trimethoprim-sulfamethoxazole_NN (_( Roche_NP ,_, Paris_NP ,_, France_NP )_) ,_, and_CC thiamphenicol_NN (_( Sanofi_NP Winthrop_NP ,_, Gentilly_NP ,_, France_NP )_) ._SENT Stock_NN solutions_NNS were_VBD prepared_VBN by_IN dissolving_VBG all_DT antibiotics_NNS except_IN telithromycin_NN in_IN sterile_JJ distilled_JJ water_NN ;_: telithromycin_NP was_VBD first_RB dissolved_VBN in_IN methanol_NN before_IN being_VBG diluted_VBN in_IN sterile_JJ distilled_JJ water_NN ._SENT Stock_NN solutions_NNS were_VBD stored_VBN at_IN -20C_NN in_IN culture_NN medium_NN ,_, and_CC dilutions_NNS were_VBD made_VBN immediately_RB prior_RB to_TO the_DT tests_NNS ._SENT The_DT plaque_NN assay_NN for_IN R._NP conorii_NP and_CC R._NP typhi_NNS was_VBD performed_VBN as_IN described_VBN previously_RB and_CC served_VBN as_IN a_DT control_NN for_IN the_DT two_CD other_JJ methods_NNS that_IN we_PP used_VBD ,_, with_IN the_DT results_NNS obtained_VBN by_IN the_DT plaque_NN assay_NN compared_VBN with_IN those_DT obtained_VBN by_IN the_DT other_JJ two_CD methods_NNS ._SENT For_IN the_DT plaque_NN assay_NN with_IN R._NP felis_NP ,_, 24-well_JJ microtiter_NN plates_NNS with_IN XTC-2_JJ cells_NNS were_VBD infected_VBN with_IN R._NP felis_NP and_CC incubated_VBN at_IN 28C_JJ in_IN Leibowitz-15_NP medium_NN ._SENT Similarly_RB ,_, plates_NNS containing_VBG Vero_NP cells_NNS were_VBD infected_VBN with_IN R._NP conorii_NP or_CC R._NP typhi_NNS and_CC incubated_VBN at_IN 32C_JJ with_IN minimum_JJ essential_JJ medium_NN ._SENT The_DT antibiotics_NNS at_IN each_DT dilution_NN were_VBD added_VBN to_TO rows_NNS of_IN infected_JJ cells_NNS ;_: positive_JJ controls_NNS consisted_VBN of_IN infected_JJ cells_NNS without_IN antibiotics_NNS in_IN the_DT medium_NN ,_, and_CC negative_JJ controls_NNS consisted_VBN of_IN uninfected_JJ cells_NNS with_IN antibiotics_NNS in_IN the_DT medium_NN ._SENT From_IN day_NN 0_CD to_TO the_DT end_NN of_IN the_DT experiment_NN ,_, three_CD wells_NNS from_IN each_DT row_NN were_VBD harvested_VBN each_DT day_NN and_CC stored_VBD at_IN -20C_NN in_IN sterile_JJ tubes_NNS for_IN the_DT PCR_NP assay_NN ._SENT Also_RB ,_, cells_NNS from_IN each_DT row_NN were_VBD stained_VBN with_IN Gimenez_NP stain_NN ,_, and_CC the_DT number_NN of_IN intracellular_JJ rickettsiae_NNS was_VBD counted_VBN at_IN x1,000_JJ magnification_NN ._SENT The_DT MIC_NN was_VBD defined_VBN as_IN the_DT lowest_JJS antibiotic_NN concentration_NN that_WDT completely_RB inhibited_VBD the_DT growth_NN of_IN the_DT rickettsiae_NNS ._SENT Experiments_NNS were_VBD performed_VBN in_IN duplicate_NN to_TO confirm_VB the_DT results_NNS ._SENT Real-time_JJ PCR_NP was_VBD performed_VBN with_IN a_DT LightCycler_NP instrument_NN (_( Roche_NP Biochemicals_NP ,_, Mannheim_NP ,_, Germany_NP )_) ,_, which_WDT is_VBZ a_DT combined_JJ fluorimeter_NN and_CC thermocycler_NN that_WDT enables_VBZ rapid_JJ (_( 45_CD min_NN )_) PCR_NP thermocycling_NN ._SENT Samples_NNS and_CC the_DT PCR_NP master_NN mixture_NN are_VBP placed_VBN in_IN 30-mul_JJ glass_NN cuvettes_NNS ,_, and_CC sample_NN detection_NN is_VBZ based_VBN on_IN the_DT principle_NN of_IN fluorescence_NN resonance_NN energy_NN transfer_NN ,_, with_IN adjacent_JJ hybridization_NN probes_NNS directed_VBN against_IN the_DT intended_JJ PCR_NP product_NN ._SENT With_IN fluorescein_NN serving_VBG as_IN the_DT donor_NN fluorophore_NN and_CC LC-Red_NP 640_NP (_( Roche_NP Biochemicals_NP )_) serving_VBG as_IN the_DT acceptor_NN fluorophore_NN ,_, the_DT presence_NN of_IN PCR_NP amplicons_NNS can_MD be_VB assessed_VBN by_IN detection_NN of_IN the_DT fluorescence_NN of_IN LC-Red_NP 640_CD ._SENT Samples_NNS can_MD be_VB assayed_VBN for_IN the_DT presence_NN of_IN this_DT signal_NN in_IN real_JJ time_NN at_IN each_DT PCR_NP cycle_NN ,_, and_CC the_DT cycle_NN number_NN at_IN which_WDT the_DT signal_NN is_VBZ first_RB detected_VBN can_MD be_VB correlated_VBN to_TO the_DT original_JJ concentration_NN of_IN DNA_NP ._SENT The_DT specificity_NN of_IN amplification_NN can_MD be_VB confirmed_VBN by_IN melting_VBG curve_NN analysis_NN ._SENT Single_JJ melting_NN peaks_NNS can_MD be_VB generated_VBN by_IN depicting_VBG the_DT negative_JJ derivative_NN of_IN fluorescence_NN versus_CC temperature_NN (_( -dF/dT_NP )_) over_IN the_DT course_NN of_IN gradual_JJ melting_NN of_IN a_DT PCR_NP product_NN ._SENT Extraction_NN of_IN DNA_NP ._SENT |_SYM After_IN the_DT harvested_VBN cells_NNS were_VBD thawed_VBN ,_, they_PP were_VBD centrifuged_VBN in_IN a_DT Beckman_NP Avanti_NP 30_CD centrifuge_NN at_IN 5,000_CD rpm_NN for_IN 10_CD min_NN ,_, the_DT supernatant_JJ was_VBD discarded_VBN ,_, and_CC the_DT pellet_NN was_VBD washed_VBN twice_RB with_IN sterile_JJ distilled_JJ water_NN before_IN being_VBG resuspended_VBN in_IN 200_CD mul_NN of_IN sterile_JJ distilled_JJ water_NN ._SENT Extraction_NN of_IN the_DT DNA_NN was_VBD performed_VBN with_IN 20_CD %_NN Chelex_NP (_( biotechnology-grade_NN chelating_VBG resin_NN [_SYM Chelex_NP 100_CD ;_: Bio-Rad_NP ,_, Richmond_NP ,_, Calif._NP ]_SYM )_) in_IN sterile_JJ water_NN ._SENT Briefly_RB ,_, 500_CD mul_NN of_IN Chelex_NP was_VBD added_VBN to_TO each_DT tube_NN of_IN centrifuged_VBN and_CC washed_VBN cells_NNS before_IN the_DT tubes_NNS were_VBD vortexed_VBN and_CC placed_VBN in_IN a_DT boiling_JJ water_NN bath_NN for_IN 30_CD min_NN ._SENT After_IN centrifugation_NN at_IN 14,000_CD rpm_NN for_IN 10_CD min_NN ,_, the_DT supernatants_NNS were_VBD harvested_VBN and_CC stored_VBN in_IN sterile_JJ tubes_NNS at_IN 4C_JJ before_IN PCR_NP was_VBD performed_VBN ._SENT PCR_NP master_NN mixture_NN ._SENT |_SYM Master_NP mixtures_NNS were_VBD prepared_VBN by_IN following_VBG the_DT instructions_NNS of_IN the_DT manufacturer_NN and_CC with_IN primers_NNS CS877F_NP (_( 5'-GGG_NP GGC_NP CTG_NP CTC_NP ACG_NP GCG_NP G-3_NP '_'' )_) and_CC CS1258R_NP (_( 5'-ATT_NP GCA_NP AAA_NP AGT_NP ACA_NP GTG_NP AAC_NP A-3_NP '_POS )_) ,_, whose_WP$ sequences_NNS are_VBP specific_JJ for_IN the_DT sequence_NN of_IN the_DT citrate_NN synthase_NN gene_NN and_CC which_WDT have_VBP been_VBN described_VBN previously_RB ._SENT The_DT 20-mul_JJ sample_NN in_IN each_DT glass_NN cuvette_NN contained_VBD 2_CD mul_NN of_IN LightCycler_NP DNA_NP Master_NP SYBR_NP Green_NP (_( Roche_NP Biochemicals_NP )_) ,_, 2.4_CD mul_NN of_IN MgCl2_NP at_IN 4_CD mM_NNS ,_, 1_CD mul_NN of_IN each_DT primer_NN at_IN 0.5_CD muM_NN ,_, 11.6_CD mul_NN of_IN sterile_JJ distilled_JJ water_NN ,_, and_CC 2_CD mul_NN of_IN extracted_VBN DNA_NN ._SENT PCR_NP cycling_NN and_CC melting_VBG curve_NN conditions_NNS ._SENT |_SYM After_IN one_CD pulse_NN centrifugation_NN to_TO allow_VB mixing_VBG and_CC to_TO drive_VB the_DT mixture_NN into_IN the_DT distal_JJ end_NN of_IN each_DT cuvette_NN ,_, the_DT tubes_NNS were_VBD placed_VBN in_IN the_DT LightCycler_NP instrument_NN ._SENT The_DT amplification_NN program_NN began_VBD with_IN a_DT denaturation_NN step_NN of_IN 95C_NN for_IN 120_CD s_NNS ,_, which_WDT was_VBD followed_VBN by_IN 40_CD cycles_NNS of_IN denaturation_NN at_IN 95C_NN for_IN 15_CD s_NNS ,_, annealing_VBG at_IN 54C_NN for_IN 8_CD s_NNS ,_, and_CC extension_NN at_IN 72C_NP for_IN 15_CD s_NNS ,_, with_IN fluorescence_NN acquisition_NN at_IN 54_CD in_IN the_DT single_JJ mode_NN ._SENT Melting_VBG curve_NN analysis_NN was_VBD done_VBN at_IN 45_CD to_TO 90C_NP (_( temperature_NN transition_NN ,_, 20C/s_JJ )_) ,_, with_IN stepwise_JJ fluorescence_NN acquisition_NN done_VBN by_IN real-time_JJ measurement_NN of_IN the_DT fluorescence_NN directly_RB in_IN the_DT clear_JJ glass_NN capillary_NN tubes_NNS ._SENT Sequence-specific_JJ standard_JJ curves_NNS were_VBD generated_VBN by_IN using_VBG 10-fold_JJ serial_JJ dilutions_NNS (_( 105_CD to_TO 106_CD copies_NNS )_) of_IN a_DT standard_JJ concentration_NN of_IN Rickettsia_NP ._SENT The_DT number_NN of_IN copies_NNS of_IN each_DT sample_NN transcript_NN was_VBD then_RB calculated_VBN from_IN the_DT standard_JJ curve_NN with_IN the_DT LightCycler_NP software_NN ._SENT The_DT MIC_NN was_VBD defined_VBN as_IN the_DT lowest_JJS antibiotic_NN concentration_NN that_WDT caused_VBD inhibition_NN of_IN growth_NN of_IN the_DT rickettsiae_NNS ,_, i.e._FW ,_, that_WDT resulted_VBD in_IN the_DT number_NN of_IN DNA_NN copies_NNS being_VBG similar_JJ to_TO that_DT on_IN day_NN 0_CD ._SENT The_DT experiments_NNS were_VBD carried_VBN out_RP in_IN duplicate_NN ._SENT The_DT Gimenez_NP staining_VBG assay_NN was_VBD easy_JJ to_TO perform_VB with_IN R._NP felis_NP ,_, but_CC counting_VBG of_IN the_DT organisms_NNS was_VBD laborious_JJ and_CC time-consuming_JJ ,_, as_RB 1,000_CD cells_NNS were_VBD examined_VBN for_IN each_DT sample_NN ._SENT The_DT results_NNS obtained_VBN with_IN the_DT reference_NN strains_NNS (_( R._NP typhi_NP and_CC R._NP conorii_NP )_) by_IN the_DT Gimenez_NP staining_VBG assay_NN were_VBD similar_JJ to_TO those_DT obtained_VBN by_IN the_DT plaque_NN assay_NN ._SENT The_DT PCR_NP assay_NN with_IN the_DT LightCycler_NP instrument_NN was_VBD rapid_JJ and_CC reproducible_JJ and_CC allowed_VBN the_DT number_NN of_IN DNA_NN copies_NNS to_TO be_VB counted_VBN precisely_RB ._SENT Figures_NNS and_CC present_VB the_DT results_NNS of_IN the_DT quantitative_JJ PCR_NP assay_NN ._SENT Figure_NN shows_VBZ the_DT melting_NN curves_NNS obtained_VBN with_IN standard_JJ concentrations_NNS of_IN R._NP felis_NP and_CC R._NP conorii_NP ,_, showing_VBG the_DT specificity_NN of_IN the_DT PCR_NP product_NN (_( a_DT single_JJ peak_NN was_VBD obtained_VBN in_IN all_DT PCRs_NN )_) ._SENT Figure_NN shows_VBZ the_DT standard_JJ calibration_NN curve_NN obtained_VBN with_IN 10-fold_JJ serial_JJ dilutions_NNS of_IN R._NP felis_NP ._SENT The_DT standard_JJ curve_NN was_VBD determined_VBN in_IN each_DT experiment_NN to_TO enable_VB the_DT results_NNS of_IN all_DT experiments_NNS to_TO be_VB correlated_VBN ._SENT In_IN Fig._NN we_PP show_VBP the_DT growth_NN kinetics_NN of_IN R._NP felis_NP ,_, R._NP conorii_NP ,_, and_CC R._NP typhi_NNS determined_VBN by_IN the_DT quantitative_JJ PCR_NP assay_NN ._SENT In_IN Vero_NP cells_NNS ,_, the_DT number_NN of_IN copies_NNS of_IN R._NP conorii_NP DNA_NP increased_VBD more_RBR rapidly_RB than_IN the_DT number_NN of_IN copies_NNS of_IN R._NP typhi_NP DNA_NP (_( 5_CD versus_IN 7_CD days_NNS )_) ,_, but_CC the_DT two_CD strains_NNS achieved_VBD a_DT zenith_NN of_IN about_RB 105_CD DNA_NN copies_NNS after_IN 6_CD to_TO 7_CD days_NNS ._SENT R._NP felis_NP grown_VBN in_IN XTC-2_JJ cells_NNS had_VBD a_DT maximum_JJ number_NN of_IN DNA_NN copies_NNS after_IN 5_CD days_NNS ._SENT In_IN the_DT antibiotic_JJ susceptibility_NN assays_NNS ,_, the_DT results_NNS obtained_VBN by_IN the_DT Gimenez_NP staining_VBG method_NN and_CC the_DT real-time_JJ PCR_NP assay_NN were_VBD consistent_JJ with_IN those_DT obtained_VBN previously_RB by_IN the_DT plaque_NN assay_NN ,_, which_WDT is_VBZ regarded_VBN as_IN the_DT "_`` gold_JJ standard_NN ._SENT "_'' The_DT MICs_NN of_IN the_DT antibiotics_NNS for_IN the_DT four_CD isolates_NNS of_IN R._NP felis_NP ,_, R._NP conorii_NP ,_, and_CC R._NP typhi_NNS determined_VBN by_IN the_DT different_JJ assays_NNS are_VBP shown_VBN in_IN Table_NP ._SENT The_DT four_CD isolates_NNS of_IN R._NP felis_NP had_VBD the_DT same_JJ antibiotic_JJ susceptibility_NN profiles_NNS ,_, being_VBG resistant_JJ to_TO amoxicillin_NN ,_, gentamicin_NN ,_, and_CC trimethoprim-sulfamethoxazole_NN ._SENT They_PP had_VBD poor_JJ susceptibilities_NNS to_TO erythromycin_NN ,_, with_IN MICs_NP ranging_VBG from_IN 8_CD to_TO 32_CD mug/ml_NN ;_: in_IN contrast_NN ,_, R._NP typhi_NNS was_VBD highly_RB sensitive_JJ (_( MIC_NP ,_, 1_CD mug/ml_NN )_) ._SENT Doxycycline_NP was_VBD the_DT most_RBS effective_JJ antibiotic_NN against_IN all_DT isolates_NNS tested_VBD ,_, with_IN MICs_NP ranging_VBG from_IN 0.06_CD to_TO 0.125_CD mug/ml_NN ._SENT Fluoroquinolone_NP compounds_NNS had_VBD MICs_NP from_IN 0.5_CD to_TO 1_CD mug/ml_NN ,_, whereas_IN the_DT MICs_NN of_IN thiamphenicol_NN were_VBD between_IN 1_CD and_CC 4_CD mug/ml_NN ._SENT Rifampin_NP was_VBD active_JJ ,_, with_IN MICs_NP ranging_VBG from_IN 0.06_CD to_TO 1_CD mug/ml_NN ._SENT The_DT new_JJ ketolide_NN compound_NN ,_, telithromycin_NN ,_, was_VBD bacteriostatic_JJ at_IN concentrations_NNS from_IN 0.5_CD to_TO 1_CD mug/ml_NN ._SENT In_IN previous_JJ studies_NNS we_PP have_VBP found_VBN that_IN plaques_NNS caused_VBN by_IN R._NP conorii_NP in_IN cell_NN cultures_NNS are_VBP larger_JJR in_IN the_DT presence_NN of_IN trimethoprim-sulfamethoxazole_NN (_( unpublished_JJ data_NNS )_) ,_, and_CC in_IN this_DT study_NN we_PP found_VBD the_DT number_NN of_IN DNA_NN copies_NNS in_IN cultures_NNS with_IN or_CC without_IN trimethoprim-sulfamethoxazole_NN to_TO be_VB almost_RB identical_JJ (_( 388,500_CD and_CC 395,000_CD copies_NNS ,_, respectively_RB )_) at_IN the_DT time_NN of_IN maximum_JJ growth_NN on_IN day_NN 7_CD of_IN culture_NN ._SENT FIG._NN 1_CD ._SENT |_SYM Melting_NP curve_NN obtained_VBN with_IN standard_JJ concentrations_NNS of_IN R._NP conorii_NP Melting_NP curve_NN obtained_VBN with_IN standard_JJ concentrations_NNS of_IN R._NP conorii_NP by_IN PCR_NP with_IN the_DT LightCycler_NP instrument_NN ._SENT The_DT specificities_NNS of_IN the_DT PCR_NP products_NNS are_VBP shown_VBN by_IN detection_NN of_IN a_DT single_JJ peak_NN ._SENT FIG._NN 2_CD ._SENT |_SYM Standard_NP calibration_NN curve_NN obtained_VBN with_IN 10-fold_JJ serial_JJ dilutions_NNS of_IN R._NP felis_NP Standard_NP calibration_NN curve_NN obtained_VBN with_IN 10-fold_JJ serial_JJ dilutions_NNS of_IN R._NP felis_NP (_( strain_NN Baton_NP Rouge_NP )_) ._SENT Quantification_NN was_VBD performed_VBN by_IN determining_VBG the_DT threshold_NN cycle_NN (_( cycle_NN number_NN )_) ._SENT The_DT threshold_NN is_VBZ defined_VBN as_IN the_DT cycle_NN at_IN which_WDT the_DT fluorescence_NN exceeds_VBZ 10_CD times_NNS the_DT standard_JJ deviation_NN of_IN the_DT mean_JJ baseline_NN emission_NN ._SENT One_CD representative_NN curve_NN and_CC its_PP$ equation_NN are_VBP given_VBN ._SENT FIG._NN 3_CD ._SENT |_SYM Kinetics_NP of_IN R._NP conorii_NP Kinetics_NP of_IN R._NP conorii_NP ,_, R._NP typhi_NNS (_( *_SYM )_) ,_, and_CC R._NP felis_NP growth_NN in_IN cell_NN culture_NN determined_VBN by_IN quantitative_JJ PCR_NP assay_NN ._SENT TABLE_NN 1_CD |_SYM In_IN vitro_NN susceptibilities_NNS of_IN rickettsial_JJ strains_NNS to_TO antibiotics_NNS Rickettsiae_NNS are_VBP gram-negative_JJ bacteria_NNS that_WDT are_VBP primarily_RB associated_VBN with_IN arthropods_NNS that_WDT are_VBP the_DT vectors_NNS of_IN human_JJ infections_NNS ._SENT Since_IN they_PP are_VBP obligate_JJ intracellular_JJ bacteria_NNS ,_, in_IN vitro_NN studies_NNS of_IN their_PP$ susceptibilities_NNS to_TO antibiotics_NNS require_VBP the_DT use_NN of_IN cell_NN culture_NN systems_NNS ._SENT In_IN our_PP$ laboratory_NN we_PP have_VBP recently_RB isolated_VBN and_CC cultured_VBN R._NP felis_NP ,_, the_DT agent_NN of_IN flea-borne_JJ spotted_JJ fever_NN ._SENT We_PP inoculate_VBP crushed_JJ cat_NN fleas_NNS ,_, in_IN which_WDT the_DT DNA_NN of_IN the_DT ELB_NP agent_NN was_VBD previously_RB detected_VBN ,_, onto_IN XTC-2_JJ cells_NNS incubated_VBN at_IN 28C_JJ ._SENT With_IN R._NP felis_NP no_DT cytopathic_JJ effects_NNS were_VBD observed_VBN in_IN XTC-2_JJ cell_NN cultures_NNS ,_, and_CC only_RB very_RB small_JJ plaques_NNS could_MD be_VB seen_VBN in_IN Vero_NP cells_NNS ,_, with_IN these_DT plaques_NNS observed_VBD only_RB after_IN 18_CD days_NNS of_IN culture_NN ._SENT As_IN it_PP was_VBD not_RB possible_JJ to_TO use_VB conventional_JJ assays_NNS to_TO determine_VB the_DT susceptibility_NN of_IN R._NP felis_NP to_TO antibiotics_NNS ,_, we_PP developed_VBD an_DT assay_NN using_VBG Gimenez_NP staining_VBG to_TO determine_VB rickettsial_JJ numbers_NNS before_IN and_CC after_IN addition_NN of_IN antibiotics_NNS to_TO the_DT culture_NN medium_NN ._SENT We_PP also_RB developed_VBD a_DT new_JJ quantitative_JJ PCR_NP assay_NN using_VBG the_DT LightCycler_NP system_NN to_TO determine_VB the_DT antibiotic_JJ susceptibilities_NNS of_IN rickettsiae_NNS ._SENT The_DT Gimenez_NP staining_VBG method_NN was_VBD too_RB laborious_JJ and_CC time-consuming_JJ to_TO be_VB a_DT recommended_JJ technique_NN ._SENT The_DT quantitative_JJ PCR_NP assay_NN with_IN the_DT LightCycler_NP instrument_NN has_VBZ already_RB been_VBN shown_VBN to_TO be_VB an_DT effective_JJ diagnostic_JJ tool_NN and_CC has_VBZ been_VBN used_VBN to_TO detect_VB antibiotic-resistant_JJ strains_NNS of_IN Mycobacterium_NN tuberculosis_NN ._SENT Our_PP$ experiments_NNS by_IN PCR_NP with_IN the_DT LightCycler_NP instrument_NN were_VBD ,_, to_TO the_DT best_JJS of_IN our_PP$ knowledge_NN ,_, the_DT first_JJ to_TO determine_VB the_DT MICs_NN of_IN antibiotics_NNS by_IN that_DT technique_NN ._SENT The_DT quantitative_JJ method_NN that_IN we_PP describe_VBP enabled_VBD us_PP to_TO determine_VB the_DT antibiotic_JJ susceptibilities_NNS of_IN fastidious_JJ Rickettsia_NP spp._NN rapidly_RB and_CC consistently_RB and_CC may_MD be_VB useful_JJ for_IN determination_NN of_IN the_DT antibiotic_JJ susceptibilities_NNS of_IN many_JJ other_JJ bacteria_NNS ._SENT The_DT susceptibility_NN results_VBZ that_IN we_PP obtained_VBD for_IN the_DT reference_NN strains_NNS ,_, R._NP conorii_NP and_CC R._NP typhi_NNS ,_, by_IN the_DT PCR_NP assay_NN were_VBD comparable_JJ to_TO those_DT obtained_VBN by_IN the_DT plaque_NN assay_NN ,_, and_CC for_IN the_DT first_JJ time_NN ,_, we_PP were_VBD able_JJ to_TO describe_VB the_DT kinetics_NN of_IN rickettsial_JJ DNA_NN during_IN the_DT rickettsial_JJ growth_NN phase_NN ._SENT These_DT were_VBD consistent_JJ with_IN our_PP$ knowledge_NN of_IN the_DT in_IN vitro_NN culture_NN characteristics_NNS of_IN rickettsiae_NNS ._SENT In_IN cell_NN culture_NN ,_, R._NP conorii_NP grows_VBZ rapidly_RB ,_, the_DT majority_NN of_IN cells_NNS are_VBP infected_VBN after_IN 3_CD to_TO 4_CD days_NNS ,_, and_CC subculturing_VBG is_VBZ generally_RB necessary_JJ after_IN 5_CD days_NNS ,_, when_WRB all_DT cells_NNS have_VBP been_VBN destroyed_VBN ._SENT R._NP typhi_NNS ,_, however_RB ,_, grows_VBZ more_RBR slowly_RB and_CC can_MD be_VB maintained_VBN for_IN 7_CD to_TO 9_CD days_NNS before_RB subculturing_VBG is_VBZ necessary_JJ ._SENT We_PP have_VBP observed_VBN similar_JJ growth_NN kinetics_NNS for_IN R._NP felis_NP in_IN XTC-2_JJ cells_NNS ,_, with_IN almost_RB all_DT cells_NNS becoming_VBG infected_JJ after_IN 5_CD days_NNS ._SENT The_DT kinetics_NN that_IN we_PP found_VBD in_IN our_PP$ PCR_NP study_NN were_VBD consistent_JJ with_IN these_DT in_IN vitro_NN culture_NN characteristics_NNS of_IN R._NP felis_NP ._SENT Finally_RB ,_, the_DT kinetics_NN of_IN growth_NN of_IN each_DT bacterium_NN enabled_VBD us_PP to_TO choose_VB the_DT best_JJS time_NN to_TO perform_VB the_DT antibiotic_JJ assay_NN ,_, i.e._FW ,_, at_IN day_NN 4_CD for_IN R._NP conorii_NP and_CC R._NP felis_NP and_CC at_IN day_NN 6_CD for_IN R._NP typhi_NNS ._SENT We_PP found_VBD that_IN beta-lactams_NNS ,_, gentamicin_NN ,_, trimethoprim-sulfamethoxazole_NN ,_, and_CC erythromycin_NN are_VBP not_RB active_JJ against_IN R._NP felis_NP ._SENT These_DT results_NNS differ_VBP from_IN those_DT reported_VBN by_IN Radulovic_NP et_FW al._FW ,_, who_WP found_VBD that_IN "_`` R._NP felis_NP "_'' was_VBD susceptible_JJ to_TO erythromycin_NN (_( MICs_NP ,_, 0.5_CD to_TO 1_CD mug/ml_NN )_) ._SENT These_DT were_VBD similar_JJ to_TO the_DT MICs_NP for_IN R._NP typhi_NNS ,_, and_CC it_PP later_RBR appeared_VBD that_IN the_DT "_`` R._NP felis_NP "_'' strain_NN that_IN they_PP studied_VBD was_VBD in_IN fact_NN a_DT strain_NN of_IN R._NP typhi_NNS ._SENT The_DT most_RBS effective_JJ antibiotics_NNS in_IN our_PP$ study_NN were_VBD doxycycline_JJ ,_, fluoroquinolones_NNS ,_, rifampin_NN ,_, thiamphenicol_NN ,_, and_CC telithromycin_NN ._SENT Our_PP$ results_NNS also_RB confirm_VBP those_DT of_IN previous_JJ experiments_NNS that_WDT showed_VBD that_DT doxycycline_NN ,_, rifampin_NN ,_, and_CC fluoroquinolones_NNS are_VBP the_DT most_RBS effective_JJ antibiotics_NNS in_IN vitro_NN against_IN all_DT strains_NNS of_IN rickettsiae_NNS ._SENT The_DT MICs_NP found_VBD in_IN our_PP$ study_NN and_CC those_DT reported_VBD previously_RB and_CC obtained_VBN by_IN the_DT plaque_NN assay_NN were_VBD lower_JJR than_IN those_DT obtained_VBN by_IN Ives_NP et_FW al._FW by_IN the_DT immunofluorescence_NN assay_NN ,_, especially_RB for_IN fluoroquinolone_NN compounds_NNS ._SENT The_DT results_NNS obtained_VBN by_IN the_DT immunofluorescence_NN assay_NN are_VBP not_RB consistent_JJ with_IN clinical_JJ experience_NN ,_, suggesting_VBG that_IN the_DT method_NN should_MD be_VB reconsidered_VBN ._SENT Patients_NNS suffering_VBG from_IN Mediterranean_JJ spotted_JJ fever_NN have_VBP been_VBN successfully_RB treated_VBN with_IN fluoroquinolones_NNS ,_, and_CC thus_RB ,_, fluoroquinolones_NNS may_MD be_VB considered_VBN a_DT safe_JJ alternative_NN to_TO tetracyclines_NNS for_IN the_DT treatment_NN of_IN rickettsial_JJ diseases_NNS ._SENT During_IN pregnancy_NN and_CC childhood_NN ,_, macrolide_NN compounds_NNS may_MD represent_VB a_DT safe_JJ alternative_NN to_TO doxycycline_NN and_CC fluoroquinolones_NNS ._SENT There_EX is_VBZ ,_, however_RB ,_, a_DT high_JJ level_NN of_IN heterogeneity_NN in_IN the_DT susceptibilities_NNS of_IN spotted_JJ fever_NN group_NN rickettsiae_NNS to_TO these_DT compounds_NNS ;_: josamycin_NN is_VBZ the_DT only_JJ antibiotic_NN whose_WP$ efficacy_NN against_IN rickettsial_JJ diseases_NNS in_IN this_DT population_NN has_VBZ been_VBN tested_VBN ,_, whereas_IN erythromycin_NN has_VBZ not_RB been_VBN shown_VBN to_TO be_VB effective_JJ ._SENT We_PP have_VBP previously_RB shown_VBN that_IN it_PP is_VBZ possible_JJ to_TO distinguish_VB the_DT typhus_NN and_CC spotted_JJ fever_NN groups_NNS of_IN rickettsiae_NNS by_IN their_PP$ susceptibilities_NNS to_TO erythromycin_NN ._SENT The_DT relative_JJ resistance_NN of_IN R._NP felis_NP to_TO erythromycin_NN is_VBZ consistent_JJ with_IN the_DT fact_NN that_IN this_DT rickettsia_NN belongs_VBZ to_TO the_DT spotted_JJ fever_NN rather_RB than_IN the_DT typhus_NN group_NN ,_, the_DT members_NNS of_IN which_WDT are_VBP susceptible_JJ to_TO erythromycin_NN ._SENT In_IN summary_NN ,_, our_PP$ report_NN describes_VBZ for_IN the_DT first_JJ time_NN the_DT susceptibilities_NNS of_IN R._NP felis_NP to_TO a_DT wide_JJ range_NN of_IN antibiotics_NNS determined_VBN by_IN a_DT new_JJ quantitative_JJ PCR_NP assay_NN ._SENT Our_PP$ results_NNS show_VBP that_DT doxycycline_NN ,_, fluoroquinolones_NNS ,_, telithromycin_NN ,_, and_CC rifampin_NN are_VBP effective_JJ against_IN the_DT organism_NN but_CC that_DT trimethoprim-sulfamethoxazole_NN ,_, beta-lactams_NNS ,_, and_CC erythromycin_NN are_VBP not_RB ._SENT This_DT new_JJ quantitative_JJ PCR_NP assay_NN should_MD be_VB developed_VBN and_CC adapted_VBN to_TO testing_VBG of_IN the_DT antibiotic_JJ susceptibilities_NNS of_IN other_JJ strict_JJ intracellular_JJ pathogens_NNS ._SENT 